AccessHope

A second opinion that doesn't make you fire your first doctor

Somewhere today, a person in a town without a major cancer center is sitting across from a community oncologist, holding a diagnosis nobody wants. The doctor is good. The doctor is also one person, facing a disease that now has hundreds of subtypes and a treatment landscape that changes by the quarter. AccessHope exists for exactly this moment - and it does something quietly radical. It puts a subspecialist who treats that one rare cancer all day, every day, on the same team as the local doctor. No flight. No relocation. No "you'll have to start over with us."

AccessHope is a health-benefits company headquartered in Duarte, California, and a wholly owned subsidiary of City of Hope, one of the nation's NCI-designated Comprehensive Cancer Centers. It sells to employers, not patients. When an employee with cancer is covered, AccessHope's experts review the case and send evidence-based recommendations straight to the treating oncologist. The patient keeps their doctor. The doctor gains a brain trust.

Cancer care depends on your zip code. It shouldn't.

Here is the uncomfortable arithmetic of American oncology: the overwhelming majority of cancer patients are treated in community settings, while the deepest expertise concentrates in a few dozen academic centers. The result is a gap. Two people with the same diagnosis can get meaningfully different care depending on whether they happen to live near one of those centers. The gap widens for rare cancers, complex cases, and anyone who can't afford to travel.

The conventional fix was to tell patients to come to the experts. AccessHope's founders thought that was backwards. Most people can't uproot their lives mid-treatment, and the clock on cancer does not pause for logistics. As founding CEO Mark Stadler liked to put it, a patient's best chance of a cure is often their first chance - and a first course of treatment built on incomplete information is hard to undo.

What if the expertise traveled instead?

In October 2020, City of Hope launched AccessHope with a $40 million investment and a deliberately contrarian premise: don't move the patient, move the knowledge. City of Hope President and CEO Robert Stone said demand from employers across the country is what pushed them to spin up a separate company. Board chair Harlan Levine, M.D., framed it as an equity project - using precision medicine and research to close the gap in outcomes, not just widen the menu of services.

It is, when you think about it, a strange thing for a hospital to build. Most health systems compete to attract patients through their doors. AccessHope was designed to help patients get great care without ever walking through City of Hope's. That is either a contradiction or a mission - and AccessHope has spent its short life arguing it's the latter.

A remote tumor board, on call

Strip away the brochure language and AccessHope's core product is an expert advisory review. A subspecialist - someone whose entire practice is, say, a single blood cancer - studies the patient's records and sends the local oncologist a written, evidence-based set of recommendations. Around that sit a cancer support team of nurse case managers, help navigating benefits and decisions, and clinical-trial matching that can surface options a community clinic might never see.

The deliberate design choice is that the recommendation goes to the doctor, not over the doctor's head. AccessHope isn't trying to replace the treating oncologist; it's trying to make that oncologist's next decision sharper. For the patient, the most visible feature is the least flashy one: they don't have to go anywhere.

The receipts: members, employers, and a who's-who of cancer centers

Ambition is cheap; distribution is not. AccessHope's case rests on how many people it actually reaches and which institutions stand behind it. The benefit now covers roughly nine million members through more than 700 employers, including over 70 Fortune 500 companies. The expertise comes from a consortium of NCI-designated Comprehensive Cancer Centers and a roster of 330-plus subspecialist oncologists spanning every cancer type.

Numbers reported by AccessHope and its parent, City of Hope. Treat the precise figures as a moving target - they keep going up.

The cancer centers behind it

Equity, dressed up as a benefits line item

It would be easy to file AccessHope under "employee perks," somewhere between the gym stipend and the snack budget. That would miss the point. The company frames its work as closing cancer disparities - making NCI-level expertise a standard part of care rather than a privilege of geography or income. The mechanism happens to be a B2B contract; the intent is that a warehouse worker in a small town gets the same caliber of thinking applied to their case as an executive who lives ten minutes from a research hospital.

There's a tidy irony in routing health equity through corporate benefits departments. But it works because that's where coverage already lives, and AccessHope would rather meet people where they are than wait for the system to reorganize itself.

The expertise gap isn't closing on its own

Cancer keeps getting more treatable and more complicated at the same time. Every new targeted therapy and trial result raises the bar for what "best care" means - and raises the odds that any single community oncologist can't track it all alone. That's the tailwind behind AccessHope: the more specialized cancer medicine becomes, the more valuable it is to have a subspecialist on the line. With fresh capital, a CEO steeped in payer economics, and a widening consortium of cancer centers, the company is betting that remote expertise becomes table stakes, not a luxury.

Back to that exam room in the town without a cancer center. The diagnosis is still the one nobody wanted. But now the local doctor isn't alone in the room - there's a subspecialist's review on the desk, written for this exact case. The patient never had to leave. The knowledge came to them. That was the whole idea, and AccessHope has spent five years turning it from a pitch into a phone number.